ReP USP - Resultado da busca

Artigo de periodico
CYP450 metabolism of a semisynthetic naphthoquinone, an anticancer drug candidate, by human liver microsomes (2022)
Costa, Edna M. A.; Carrão, Daniel Blascke ; Bucci, Jade Lorena Mariano; Oliveira, Anderson Rodrigo Moraes de ; Machado, Tallita M.; Ferreira, Vitor F.; Lima, Émerson S.; Vasconcellos, Marne C.; Magalhães, Igor R. S.
Source: Journal of the Brazilian Chemical Society. Unidade: FFCLRP
Subjects: ANTINEOPLÁSICOS, AVALIAÇÃO DE MEDICAMENTOS, FARMACOCINÉTICA, FÁRMACOS, BIOTRANSFORMAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Edna M. A. et al. CYP450 metabolism of a semisynthetic naphthoquinone, an anticancer drug candidate, by human liver microsomes. Journal of the Brazilian Chemical Society, v. 33, n. 10, p. 1145-1153, 2022Tradução . . Disponível em: https://doi.org/10.21577/0103-5053.20220034. Acesso em: 10 nov. 2024.
APA
Costa, E. M. A., Carrão, D. B., Bucci, J. L. M., Oliveira, A. R. M. de, Machado, T. M., Ferreira, V. F., et al. (2022). CYP450 metabolism of a semisynthetic naphthoquinone, an anticancer drug candidate, by human liver microsomes. Journal of the Brazilian Chemical Society, 33( 10), 1145-1153. doi:10.21577/0103-5053.20220034
NLM
Costa EMA, Carrão DB, Bucci JLM, Oliveira ARM de, Machado TM, Ferreira VF, Lima ÉS, Vasconcellos MC, Magalhães IRS. CYP450 metabolism of a semisynthetic naphthoquinone, an anticancer drug candidate, by human liver microsomes [Internet]. Journal of the Brazilian Chemical Society. 2022 ; 33( 10): 1145-1153.[citado 2024 nov. 10 ] Available from: https://doi.org/10.21577/0103-5053.20220034
Vancouver
Costa EMA, Carrão DB, Bucci JLM, Oliveira ARM de, Machado TM, Ferreira VF, Lima ÉS, Vasconcellos MC, Magalhães IRS. CYP450 metabolism of a semisynthetic naphthoquinone, an anticancer drug candidate, by human liver microsomes [Internet]. Journal of the Brazilian Chemical Society. 2022 ; 33( 10): 1145-1153.[citado 2024 nov. 10 ] Available from: https://doi.org/10.21577/0103-5053.20220034
Artigo de periodico
RNA sequencing data of different grade astrocytoma cell lines (2021)
Sousa, Juliana Ferreira de; Silva, Patrick da; Serafim, Rodolfo Bortolozo; Nociti, Ricardo Perecin; Moreira, Cristiano Gallina; Silva Junior, Wilson Araújo da ; Valente, Valéria
Source: Data in Brief. Unidades: FMRP, FZEA
Subjects: NEOPLASIAS CEREBRAIS, ASTROCITOMA, PERFILAÇÃO DA EXPRESSÃO GÊNICA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUSA, Juliana Ferreira de et al. RNA sequencing data of different grade astrocytoma cell lines. Data in Brief, v. 34, p. 1-13, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.dib.2020.106643. Acesso em: 10 nov. 2024.
APA
Sousa, J. F. de, Silva, P. da, Serafim, R. B., Nociti, R. P., Moreira, C. G., Silva Junior, W. A. da, & Valente, V. (2021). RNA sequencing data of different grade astrocytoma cell lines. Data in Brief, 34, 1-13. doi:10.1016/j.dib.2020.106643
NLM
Sousa JF de, Silva P da, Serafim RB, Nociti RP, Moreira CG, Silva Junior WA da, Valente V. RNA sequencing data of different grade astrocytoma cell lines [Internet]. Data in Brief. 2021 ; 34 1-13.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.dib.2020.106643
Vancouver
Sousa JF de, Silva P da, Serafim RB, Nociti RP, Moreira CG, Silva Junior WA da, Valente V. RNA sequencing data of different grade astrocytoma cell lines [Internet]. Data in Brief. 2021 ; 34 1-13.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.dib.2020.106643
Artigo de periodico
Biological properties and chemical composition of essential oil from Nectandra megapotamica (Spreng.) Mez. leaves (Lauraceae) (2020)
Almeida, Karoliny C. R.; Silva, Bruna B.; Alves, Cassia C. F.; Vieira, Tatiana Manzini ; Crotti, Antonio Eduardo Miller ; Souza, João M.; Martins, Carlos H. G.; Ribeiro, Arthur B.; Squarisi, Iara S.; Tavares, Denise Crispim ; Bernabé, Laura dos S.; Magalhães, Lizandra G.; Miranda, Mayker L. D.
Source: Natural Product Research. Unidade: FFCLRP
Subjects: ANTINEOPLÁSICOS, ANTIPROTOZOÁRIOS, CROMATOGRAFIA, ESPECTROMETRIA DE MASSAS, MAGNOLIALES, LEISHMANIA, SESQUITERPENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMEIDA, Karoliny C. R. et al. Biological properties and chemical composition of essential oil from Nectandra megapotamica (Spreng.) Mez. leaves (Lauraceae). Natural Product Research, v. 34, n. 21, p. 3149-3153, 2020Tradução . . Disponível em: https://doi.org/10.1080/14786419.2019.1608539. Acesso em: 10 nov. 2024.
APA
Almeida, K. C. R., Silva, B. B., Alves, C. C. F., Vieira, T. M., Crotti, A. E. M., Souza, J. M., et al. (2020). Biological properties and chemical composition of essential oil from Nectandra megapotamica (Spreng.) Mez. leaves (Lauraceae). Natural Product Research, 34( 21), 3149-3153. doi:10.1080/14786419.2019.1608539
NLM
Almeida KCR, Silva BB, Alves CCF, Vieira TM, Crotti AEM, Souza JM, Martins CHG, Ribeiro AB, Squarisi IS, Tavares DC, Bernabé L dos S, Magalhães LG, Miranda MLD. Biological properties and chemical composition of essential oil from Nectandra megapotamica (Spreng.) Mez. leaves (Lauraceae) [Internet]. Natural Product Research. 2020 ; 34( 21): 3149-3153.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1080/14786419.2019.1608539
Vancouver
Almeida KCR, Silva BB, Alves CCF, Vieira TM, Crotti AEM, Souza JM, Martins CHG, Ribeiro AB, Squarisi IS, Tavares DC, Bernabé L dos S, Magalhães LG, Miranda MLD. Biological properties and chemical composition of essential oil from Nectandra megapotamica (Spreng.) Mez. leaves (Lauraceae) [Internet]. Natural Product Research. 2020 ; 34( 21): 3149-3153.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1080/14786419.2019.1608539
Artigo de periodico
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial (2017)
Prince, H. Miles; Kim, Youn H.; Horwitz, Steven M.; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A.; Ortiz-Romero, Pablo L.; Akilov, Oleg E.; Geskin, Larisa; Trotman, Judith; Taylor, Kerry; Dalle, Stephane; Weichenthal, Michael; Walewski, Jan; Fisher, David; Dréno, Brigitte; Stadler, Rudolf; Feldman, Tatyana; MKuzel, Timothy; Wang, Yinghui; Palanca-Wessels, Maria Corinna; Zagadailov, Erin; Trepicchio, William L; Zhang, Wenwen; Lin, Hui-Min; Liu, Yi; Huebner, Dirk; Little, Meredith; Whittaker, Sean; Duvic, Madeleine
Source: Lancet. Unidade: FM
Subjects: LINFOMA, ESTRATÉGIAS TERAPÊUTICAS, ANTINEOPLÁSICOS, MANIFESTAÇÕES CUTÂNEAS, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRINCE, H. Miles et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, v. 390, n. 10094, p. 555-566, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)31266-7. Acesso em: 10 nov. 2024.
APA
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., et al. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390( 10094), 555-566. doi:10.1016/S0140-6736(17)31266-7
NLM
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, MKuzel T, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin H-M, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [Internet]. Lancet. 2017 ; 390( 10094): 555-566.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/S0140-6736(17)31266-7
Vancouver
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, MKuzel T, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin H-M, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [Internet]. Lancet. 2017 ; 390( 10094): 555-566.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/S0140-6736(17)31266-7
Artigo de periodico
Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society (2016)
Sholl, Lynette M.; Aisner, Dara L.; Allen, Timothy Craig; Beasley, Mary Beth; Borczuk, Alain C.; Cagle, Philip T.; Capelozzi, Vera; Dacic, Sanja; Hariri, Lida; Kerr, Keith M.; Lantuejoul, Sylvie; Mino-Kenudson, Mari; Raparia, Kirtee; Rekhtman, Natasha; Roy-Chowdhuri, Sinchita; Thunnissen, Eric; Tsao, Ming Sound; Yatabe, Yasushi
Source: Archives of Pathology and Laboratory Medicine. Unidade: FM
Subjects: FÁRMACOS, IMUNOTERAPIA, ANTINEOPLÁSICOS, APOPTOSE, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SHOLL, Lynette M. et al. Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, v. 140, p. 341-344, 2016Tradução . . Disponível em: http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2015-0506-SA. Acesso em: 10 nov. 2024.
APA
Sholl, L. M., Aisner, D. L., Allen, T. C., Beasley, M. B., Borczuk, A. C., Cagle, P. T., et al. (2016). Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 140, 341-344. doi:10.5858/arpa.2015-0506-SA
NLM
Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y. Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society [Internet]. Archives of Pathology and Laboratory Medicine. 2016 ; 140 341-344.[citado 2024 nov. 10 ] Available from: http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2015-0506-SA
Vancouver
Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y. Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society [Internet]. Archives of Pathology and Laboratory Medicine. 2016 ; 140 341-344.[citado 2024 nov. 10 ] Available from: http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2015-0506-SA
Artigo de periodico
Inhibition of Aurora Kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells (2012)
Borges, Kleiton Silva; Gamero, Angel Mauricio Castro; Moreno, Daniel Antunes; Silveira, Vanessa da Silva; Brassesco, Maria Sol; Queiroz, Rosane Gomes de Paula; Oliveira, Harley Francisco de; Carlotti Júnior, Carlos Gilberto; Scrideli, Carlos Alberto; Tone, Luiz Gonzaga
Source: Journal of Cancer Research and Clinical Oncology. Unidade: FMRP
Subjects: NEOPLASIAS CEREBRAIS, PROTEÍNAS QUINASES, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BORGES, Kleiton Silva et al. Inhibition of Aurora Kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. Journal of Cancer Research and Clinical Oncology, v. 138, n. 3, p. 405-414, 2012Tradução . . Disponível em: https://doi.org/10.1007/s00432-011-1111-0. Acesso em: 10 nov. 2024.
APA
Borges, K. S., Gamero, A. M. C., Moreno, D. A., Silveira, V. da S., Brassesco, M. S., Queiroz, R. G. de P., et al. (2012). Inhibition of Aurora Kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. Journal of Cancer Research and Clinical Oncology, 138( 3), 405-414. doi:10.1007/s00432-011-1111-0
NLM
Borges KS, Gamero AMC, Moreno DA, Silveira V da S, Brassesco MS, Queiroz RG de P, Oliveira HF de, Carlotti Júnior CG, Scrideli CA, Tone LG. Inhibition of Aurora Kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells [Internet]. Journal of Cancer Research and Clinical Oncology. 2012 ; 138( 3): 405-414.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1007/s00432-011-1111-0
Vancouver
Borges KS, Gamero AMC, Moreno DA, Silveira V da S, Brassesco MS, Queiroz RG de P, Oliveira HF de, Carlotti Júnior CG, Scrideli CA, Tone LG. Inhibition of Aurora Kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells [Internet]. Journal of Cancer Research and Clinical Oncology. 2012 ; 138( 3): 405-414.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1007/s00432-011-1111-0
Artigo de periodico
Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line (2010)
Carminati, Patricia de Oliveira; Mello, Stephano Spano; Fachin, Ana Lúcia; Junta, Cristina Moraes; Sandrin-Garcia, Paula; Carlotti Júnior, Carlos Gilberto; Donadi, Eduardo Antônio; Passos, Geraldo Aleixo Silva; Sakamoto-Hojo, Elza Tiemi
Source: Genetics and Molecular Biology. Unidades: FMRP, FORP, FFCLRP
Subjects: SISTEMA NERVOSO CENTRAL, ANTINEOPLÁSICOS, EXPRESSÃO GÊNICA, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARMINATI, Patricia de Oliveira et al. Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line. Genetics and Molecular Biology, v. 33, n. 1, p. 159-168, 2010Tradução . . Disponível em: https://doi.org/10.1590/s1415-47572010005000013. Acesso em: 10 nov. 2024.
APA
Carminati, P. de O., Mello, S. S., Fachin, A. L., Junta, C. M., Sandrin-Garcia, P., Carlotti Júnior, C. G., et al. (2010). Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line. Genetics and Molecular Biology, 33( 1), 159-168. doi:10.1590/s1415-47572010005000013
NLM
Carminati P de O, Mello SS, Fachin AL, Junta CM, Sandrin-Garcia P, Carlotti Júnior CG, Donadi EA, Passos GAS, Sakamoto-Hojo ET. Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line [Internet]. Genetics and Molecular Biology. 2010 ; 33( 1): 159-168.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1590/s1415-47572010005000013
Vancouver
Carminati P de O, Mello SS, Fachin AL, Junta CM, Sandrin-Garcia P, Carlotti Júnior CG, Donadi EA, Passos GAS, Sakamoto-Hojo ET. Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line [Internet]. Genetics and Molecular Biology. 2010 ; 33( 1): 159-168.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1590/s1415-47572010005000013

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Funding Agencies

Indexado em

Non normalized affiliation